OBJECTIVES: Psoriasis (PsO) is associated with a substantial comorbidity burden. However, limited data on comorbidity incidence are available for PsO patients in the US. This study compared the incidence of newly diagnosed comorbidities among PsO patients versus demographically matched controls. METHODS: PsO patients ≥20 years old with ≥1 inpatient or ≥2 nonrule-out PsO diagnoses (ICD-9-CM code 696.1) were identified in the Truven Health MarketScan Commercial and Medicare Supplemental Databases (January 2000–September 2015), with the first PsO diagnosis as the index date. Controls without PsO diagnosis were matched 1:1 to PsO patients on birth year, gender, and geographical region. All individuals were required to have ≥24 months of continuous enrollment prior to index date, and patients with a comorbidity of interest in the prior 24 months were excluded from analysis. Individuals were followed post-index until loss to follow-up, end of continuous enrollment, or end of study period. Incidence rates of PsO-related comorbidities were compared between the PsO and control groups. Hazard ratios were estimated using Cox proportional hazards models adjusted for baseline characteristics including comorbidities and insurance plan type. RESULTS: A total of 114,824 PsO patients and matched controls were included; mean age was 53 years and 46% were male. Incidence rates were higher for comorbidities among PsO patients including cardiovascular and metabolic diseases, autoimmune conditions, depression, anxiety, and lymphoma (all P<0.05). The most common comorbidities in both groups were hyperlipidemia (PsO vs control, incidence rate per 1000 person-years: 127.5 vs 102.8), hypertension (94.3 vs 80.6), depression (33.3 vs 24.9), anxiety (32.3 vs 25.1), and obesity (33.1 v. 24.1). In adjusted Cox models, PsO patients were more likely to develop all comorbidities described compared with matched controls, with all hazard ratios >1 (all P<0.05). CONCLUSIONS: Compared with demographically matched non-PsO controls, PsO patients were more likely to develop PsO-related comorbidities.